share_log

信达生物:IBI363获国家药监局纳入突破性治疗药物品种,治疗晚期黑色素瘤

INNOVENT BIO: IBI363 has been included in the list of breakthrough therapeutic drugs by the National Medical Products Administration for the treatment of advanced melanoma.

Breakings ·  Mar 31 00:11

On March 31, INNOVENT BIO announced that its globally pioneering PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 has been included in the list of breakthrough therapeutic drugs (BTD) by the Drug Evaluation Center (CDE) of the National Medical Products Administration (NMPA) of China, with the intended indication being unresectable locally advanced or metastatic acral and mucosal melanoma that has not previously undergone systemic treatment.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 805

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.